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Monoclonal antibodies are effective therapies for many disorders, but their nature and use continues to
evolve as technologies emerge to improve their drug-like qualities. In this issue of Structure, Schmitz and
colleagues report on structural and biophysical characterizations of single-domain ‘‘nanobodies’’ from
llamas that target the epidermal growth factor receptor by both old and new mechanisms.Over 100 years ago, Paul Ehrlich coined
the terms ‘‘magic bullet’’ to describe com-
pounds that specifically bind and deliver a
toxin to diseased cells and ‘‘antibody’’ to
describe the magic bullets in immune
sera. After notable successes treating
infectious diseases like diphtheria, anti-
bodies failed to live up to much of their
initial therapeutic promise owing to
difficulties preparing antibodies of appro-
priate specificity as well as human
immune responses to antisera raised in
animals. These problems were largely
overcome by the development of mono-
clonal antibody technology in the mid-
1970s (Ko¨hler and Milstein, 1975) and
the engineering of humanized antibodies
in the late-1980s (Jones et al., 1986),
which enabled large-scale production of
antibodies with defined specificities and
minimal immunogenicity. These ad-
vances opened the gates to modern
antibody therapy, and nearly three-dozen
monoclonal antibody therapies have
received FDA approval since 1994,
mostly to treat cancer and autoimmune
disorders.
Abnormal activity of the epidermal
growth factor receptor (EGFR) is associ-
ated with many cancers, and among the
FDA-approved antibody therapies are
Cetuximab (Erbitux) and Panitumumab
(Vectibix), which target EGFR and are
used to treat colorectal and head-and-
neck cancers (Noguchi et al., 2013).
EGFR is the archetypal receptor tyrosine
kinase and consists of an extracellular
ligand-binding region composed of four
subdomains followed by a single mem-
brane-spanning region, a cytoplasmic
tyrosine kinase domain, and a C-terminal
tail that is phosphorylated during activa-
tion and recruits downstream signaling ef-
fectors (Burgess et al., 2003). Crystallo-1072 Structure 21, July 2, 2013 ª2013 Elsevigraphic studies have shown that in the
absence of ligand, the extracellular region
adopts a folded-over or ‘‘tethered’’
conformation in which an extended loop
from the second domain contacts amem-
brane-proximal pocket in the fourth
domain (Figure 1) (Burgess et al., 2003).
Ligand-contacting regions on the first
and third domains are held too far apart
to bind ligand simultaneously in the teth-
ered conformation, and high-affinity
ligand binding requires a large domain re-
arrangement to an ‘‘extended’’ conforma-
tion in which the ligand-binding regions
are brought close together. In this
extended conformation, the previously
buried loop on the second domain be-
comes exposed and mediates reciprocal
contacts with the homologous loop on
another receptor to form active receptor
dimers (Figure 1) (Burgess et al., 2003).
In previously published work, Ferguson
and colleagues showed that Cetuximab
binds to the ligand-binding region on the
EGFR third domain and blocks both
ligand binding and rearrangement of the
receptor to the extended conformation
(Li et al., 2005). They also showed that
another anti-EGFR antibody,Matuzumab,
binds to the third domain of EGFR, but
does not clash with ligand binding and
appears to act by sterically preventing
EGFR from adopting the extended
conformation of active dimers (Schmiedel
et al., 2008). In the article by Schmitz et al.
(2013) in this issue of Structure, these
observations are now extended to struc-
tural and biophysical characterizations of
three EGFR-binding nanobodies, 7D12,
EgA1, and 9G8, which are being devel-
oped as potential anti-EGFR therapeutics
or diagnostics. Nanobodies are anti-
bodies derived from camelids—llamas in
this case—that consist of a heavy chainer Ltd All rights reservedand no light chain (Vincke and Muylder-
mans, 2012). Nanobodies have generated
much interest because of several poten-
tial advantages over normal antibodies
as therapeutics and diagnostics. Their
smaller size may allow greater tumor
penetration, they are easier and less
costly to produce, and simple modifica-
tions have been shown to extend their
serum half-life and functionality.
Another potential advantage of nano-
bodies is that their smaller antigen-
binding surface enables them to recog-
nize concave epitopes less accessible to
conventional antibodies, as illustrated by
the work of Schmitz et al. (2013). Two of
the three anti-EGFR nanobodies studied,
EgA1 and 9G8, bind to EGFR at a hinge
region between the second and third
extracellular domains. This hinge is the
focal point of domain movement in
EGFR when ligand binds, and by con-
tacting the domains flanking this hinge,
these nanobodies appear to lock EGFR
in the inactive, tethered conformation.
Like Matuzumab, these nanobodies do
not block ligand binding to EGFR and
may have an advantage as therapeutics
in that their effects cannot be overcome
by high ligand concentrations. Unlike
the conventional antibody Matuzumab,
EgA1 and 9G8 are able to bind EGFR in
a small concave pocket owing to their
smaller antigen-contacting surface, and
it will be interesting to see whether this
‘‘lock-down’’ of the inactive EGFR confor-
mation will translate to better inhibition of
EGFR activity.
The third anti-EGFR nanobody studied,
7D12, binds EGFR at a site that overlaps
its ligand binding site and blocks ligand
binding like Cetuximab, showing, per-
haps not surprisingly, that nanobodies
can functionally mimic conventional
Figure 1. Activation and Inhibition of EGFR Extracellular Regions
(A) The EGFR extracellular region is composed of four subdomains: I (blue), II
(green), III (yellow), and IV (red). In the absence of ligand, a loop from domain II
contacts a pocket in domain IV and maintains EGFR in a tethered conforma-
tion in which ligand binding surfaces on domains I and III are too far apart to
contact ligand simultaneously. Ligand binding stabilizes a domain rearrange-
ment that exposes the domain II loop, which mediates receptor dimerization
and conversion to a signaling-competent state.
(B) Cetuximab and the nanobody 7D12 bind to the EGFR ligand binding site,
competing for ligand binding and sterically blocking the extended conforma-
tion of the active dimer. The nanobodies EgA1 and 9G8 bind at the hinge
region between domains II and III and preclude conversion to the extended
conformation without competing for ligand binding.
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it will be interesting to parse
the contributions of various
mechanisms to anti-EGFR
therapeutic activity—anti-
body-dependent cellular cy-
toxicity (ADCC) versus block-
ing ligand versus blocking an
active conformation (Noguchi
et al., 2013). These mecha-
nisms may then be engi-
neered into optimal therapeu-
tics or perhaps targeted with
combined therapies. The
history of anti-homolog of
EGFR 2 (HER2) antibody
therapy illustrates the value
of this approach. The EGFR
homolog HER2 is overex-
pressed and abnormally
active in 20%–25% of breast
and gastric cancers (Slamonet al., 1987), and the anti-HER2 antibody
Trastuzumab (Herceptin) is used to treat
these cancers. First approved in 1998,
Trastuzumab does not block HER2 dimer-
ization or signaling, but rather appears to
work through ADCC and other mecha-
nisms (Arteaga et al., 2012). Another
anti-HER2 antibody, Pertuzumab (Per-
jeta), does block HER2 dimerization and
signaling (Arteaga et al., 2012), and the
increased effectiveness of Trastuzumab
when given with Pertuzumab led to FDA
approval of this combination therapy last
year. Not to stop there, and perhaps
realizing Ehrlich’s original dream of magicbullets, a toxin-conjugated form of Trastu-
zumab called Trastuzumab-emtansine
(T-DM1 or Kadcyla) (Arteaga et al., 2012)
appears to have even greater anti-HER2
efficacy and was approved earlier this
year for treatment of late stage breast
cancer. Trials of T-DM1 in earlier stage
cancers are ongoing.
The evolution of anti-HER2 therapies
highlights the value of determining the
mechanism of antibody therapeutics to
enable continued optimization of thera-
peutics. By uncovering novel inhibitory
mechanisms with novel agents, the
molecular characterization of anti-EGFRStructure 21, July 2, 2013 ª2013 Elsevnanobodies described in
this issue charts an impor-
tant new path toward
improved cancer drugs and
diagnostics.
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